- Home
- NUVB vs GCI Comparison
NUVB vs GCI Comparison
Compare NUVB & GCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- GCI
- Stock Information
- Founded
- NUVB 2018
- GCI 1997
- Country
- NUVB United States
- GCI United States
- Employees
- NUVB N/A
- GCI N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- GCI Newspapers/Magazines
- Sector
- NUVB Health Care
- GCI Consumer Discretionary
- Exchange
- NUVB Nasdaq
- GCI Nasdaq
- Market Cap
- NUVB 850.3M
- GCI 854.6M
- IPO Year
- NUVB N/A
- GCI N/A
- Fundamental
- Price
- NUVB $2.62
- GCI $5.19
- Analyst Decision
- NUVB Strong Buy
- GCI Buy
- Analyst Count
- NUVB 6
- GCI 3
- Target Price
- NUVB $6.17
- GCI $5.37
- AVG Volume (30 Days)
- NUVB 2.1M
- GCI 1.5M
- Earning Date
- NUVB 11-06-2024
- GCI 10-31-2024
- Dividend Yield
- NUVB N/A
- GCI N/A
- EPS Growth
- NUVB N/A
- GCI N/A
- EPS
- NUVB N/A
- GCI N/A
- Revenue
- NUVB $2,162,000.00
- GCI $2,557,445,000.00
- Revenue This Year
- NUVB N/A
- GCI N/A
- Revenue Next Year
- NUVB N/A
- GCI N/A
- P/E Ratio
- NUVB N/A
- GCI N/A
- Revenue Growth
- NUVB N/A
- GCI N/A
- 52 Week Low
- NUVB $1.22
- GCI $1.83
- 52 Week High
- NUVB $4.16
- GCI $5.93
- Technical
- Relative Strength Index (RSI)
- NUVB 49.69
- GCI 45.58
- Support Level
- NUVB $2.44
- GCI $4.83
- Resistance Level
- NUVB $3.07
- GCI $5.80
- Average True Range (ATR)
- NUVB 0.17
- GCI 0.23
- MACD
- NUVB -0.01
- GCI -0.03
- Stochastic Oscillator
- NUVB 43.26
- GCI 33.93
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.